+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Vulvodynia Treatment Market - Global Forecast 2026-2032- Product Image
Vulvodynia Treatment Market - Global Forecast 2026-2032- Product Image
Sale

Vulvodynia Treatment Market - Global Forecast 2026-2032

  • Report

  • 196 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4807789
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Vulvodynia Treatment Market is projected to reach USD 2.25 Billion in 2026. It is expected to continue growing at a CAGR of 6.39%, reaching USD 3.28 Billion by 2032.

Vulvodynia treatment is moving from a narrowly symptomatic approach toward multidisciplinary, evidence-informed care for chronic vulvar pain lasting at least three months without a clearly identifiable cause. Peer-reviewed epidemiology has shown that vulvodynia affects a meaningful share of women across reproductive and postmenopausal ages, with lifetime prevalence estimates commonly cited in the high single digits to mid-teens, yet diagnosis remains delayed because symptoms overlap with infections, dermatologic disease, pelvic floor dysfunction, genitourinary syndrome of menopause, and neuropathic pain.

For healthcare providers, payers, and life sciences organizations, the opportunity lies in improving earlier recognition, stratified treatment pathways, and longitudinal outcomes measurement. High-value vulvodynia care increasingly combines patient education, vulvar skin care, pelvic floor physical therapy, psychosexual counseling, cognitive behavioral therapy, topical therapies, neuropathic pain agents, hormonal treatment when indicated, and procedural options for selected localized provoked vestibulodynia cases.

Transformative Shifts in the Vulvodynia Care Landscape

The vulvodynia treatment landscape is being reshaped by stronger recognition of chronic pelvic pain as a biopsychosocial condition rather than a single-organ disorder. Clinical guidance increasingly emphasizes ruling out identifiable causes, using validated pain and sexual function measures, assessing pelvic floor muscle involvement, and referring patients to pelvic floor physical therapy or pain specialists when conservative care is insufficient.

Another major shift is the expansion of women’s health investment beyond fertility and contraception into chronic gynecologic pain, sexual wellness, menopause care, and digital therapeutics. This creates demand for clinician education, standardized diagnostic workflows, non-opioid pain management, integrated behavioral health, and patient-centered care models that address quality of life, dyspareunia, anxiety, depression, sleep disruption, and relationship impact.

Cumulative Impact of Artificial Intelligence on Vulvodynia Treatment

Artificial intelligence can improve vulvodynia care by supporting earlier detection, risk stratification, and clinical decision support across fragmented care pathways. Natural language processing can help identify recurring symptom patterns in electronic health records, such as chronic burning, provoked vestibular pain, recurrent negative infection testing, dyspareunia, pelvic floor tenderness, vulvar allodynia, and repeated empiric antifungal use.

AI also has potential in virtual triage, patient-reported outcome tracking, pelvic floor rehabilitation adherence, and real-world evidence generation. However, clinical adoption must be governed by privacy safeguards, bias testing, transparent validation, and clinician oversight because vulvar pain is underreported, culturally sensitive, and often misclassified in structured health data.

Key Regional Insights Across Vulvodynia Treatment Markets

North America remains highly influential in vulvodynia treatment awareness, specialty gynecology, pelvic pain clinics, pelvic floor physical therapy access, and women’s health digital care adoption, with the United States driving much of the innovation and Canada benefiting from guideline-based primary care and publicly funded health services. Europe shows strong multidisciplinary care capacity through gynecology, dermatology, urology, physiotherapy, pain medicine, and psychosexual medicine, particularly in the United Kingdom, Germany, France, Italy, and Spain, while reimbursement, referral pathways, and waiting times vary widely across health systems.

Asia-Pacific is gaining momentum as women’s health awareness, urban specialty care, and telehealth expand in China, India, Japan, Australia, and South Korea; Australia is especially notable for pelvic health physiotherapy integration, while Japan and South Korea benefit from advanced diagnostics and structured specialist care. Latin America, the Middle East, and Africa remain underpenetrated because of specialist shortages, stigma around sexual pain, uneven access to pelvic floor rehabilitation, and limited chronic pelvic pain coding, but these regions present long-term care-improvement potential through clinician training, culturally appropriate education, telemedicine, and integration with reproductive health and menopause services.

Key Group Insights for Vulvodynia Treatment Adoption

Within ASEAN, rising urban healthcare investment, broader smartphone access, and telemedicine adoption can improve access to gynecology, sexual health counseling, and pelvic rehabilitation, although cultural barriers often suppress reporting of vulvar pain and dyspareunia. GCC markets are positioned for premium women’s health services through hospital modernization, private specialty care, and medical tourism infrastructure, while the European Union benefits from cross-border clinical research capacity, harmonized medical device regulation, data protection standards, and multidisciplinary pain management practices.

BRICS economies represent a large unmet-need base due to population scale, growing middle-class healthcare spending, and expanding digital health infrastructure, particularly in Brazil, India, China, and South Africa, though access remains uneven between metropolitan and rural settings. G7 countries remain the most commercially mature because of specialty care density, reimbursement capacity, research output, and patient advocacy visibility, while NATO member markets overlap strongly with advanced healthcare systems where chronic pelvic pain pathways, non-opioid pain strategies, and women’s health service integration are increasingly formalized.

Key Country Insights in Vulvodynia Treatment

The United States is the most active environment for vulvodynia treatment innovation, supported by specialty pelvic pain centers, women’s health startups, pelvic floor therapy networks, and high patient advocacy visibility. Canada shows steady adoption through primary care referral models and publicly funded specialty services, while Mexico and Brazil present unmet demand driven by urban private care growth, improving gynecologic awareness, and expanding access to telehealth-enabled specialist consultation.

In Europe, the United Kingdom, Germany, France, Italy, and Spain benefit from strong clinical expertise in gynecology, dermatology, pain care, physiotherapy, and psychosexual medicine, but face variable wait times, reimbursement pathways, and regional service availability; Russia has specialist capacity in major cities but uneven access across regions. China and India offer scale and rapid digital health adoption, Japan and South Korea bring advanced diagnostics and conservative care models, and Australia stands out for pelvic health physiotherapy integration, chronic pain literacy, and public awareness of women’s pelvic health conditions.

Actionable Recommendations for Industry Leaders

Industry vendors should prioritize education-first market development because vulvodynia remains underdiagnosed and frequently treated as a recurrent infection before chronic pain is recognized. Practical actions include training gynecologists and primary care clinicians on differential diagnosis, building referral networks with pelvic floor physical therapists, integrating behavioral health and sexual counseling, and using validated patient-reported outcomes to demonstrate clinical value.

Organizations should invest in non-opioid multimodal care, evidence generation, and culturally sensitive patient engagement. The strongest strategies will combine clinical credibility, reimbursement evidence, real-world outcomes, digital adherence support, and partnerships with women’s health clinics, pain centers, academic researchers, professional associations, and patient advocacy organizations.

Research Methodology for Vulvodynia Treatment Insights

The executive summary is based on a structured secondary research approach covering peer-reviewed clinical literature, gynecology and pain guidance, public health sources, regulatory frameworks, reimbursement patterns, and healthcare delivery trends. Insights were triangulated across epidemiology, diagnostic criteria, clinical practice, digital health adoption, regional care infrastructure, and treatment modality utilization.

The methodology emphasizes verified information over speculative claims. Market interpretation focuses on observable indicators such as prevalence ranges in published studies, recognized diagnostic criteria, therapy availability, specialist access, telehealth adoption, pelvic floor rehabilitation capacity, clinical guideline alignment, patient advocacy activity, and the maturity of women’s health investment ecosystems.

Conclusion: The Future of Vulvodynia Treatment

Vulvodynia treatment is entering a more structured phase as clinicians, payers, and innovators recognize the burden of chronic vulvar pain on sexual health, mental health, relationships, and daily function. The ecosystem is not defined by a single therapy but by the ability to deliver coordinated, individualized, and outcomes-based care across gynecology, pelvic floor rehabilitation, pain medicine, dermatology, psychology, and sexual medicine.

Sustainable progress will depend on earlier diagnosis, stronger referral pathways, validated outcomes, patient education, and responsible use of digital and AI-enabled tools. Organizations that address underdiagnosis, reduce stigma, and build trusted multidisciplinary solutions will be best positioned in the evolving vulvodynia treatment ecosystem.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Vulvodynia Treatment Market, by Treatment Type
7.1. Introduction
7.2. Non-Pharmacological Treatment
7.2.1. Physical Therapy
7.2.2. Psychological Therapy
7.2.3. Neuromodulation / Device-Based Therapy
7.3. Pharmacological Treatment
7.3.1. Topical Treatments
7.3.2. Oral Medications
7.3.3. Hormonal Therapies
8. Vulvodynia Treatment Market, by Route Of Administration
8.1. Introduction
8.2. Topical
8.3. Oral
8.4. Injectable
9. Vulvodynia Treatment Market, by Prescription Status
9.1. Introduction
9.2. Prescription
9.3. Over-The-Counter
10. Vulvodynia Treatment Market, by Line Of Therapy
10.1. Introduction
10.2. First-Line
10.3. Second-Line
10.4. Third-Line
10.5. Refractory Care
11. Vulvodynia Treatment Market, by Duration
11.1. Introduction
11.2. Short-Term Therapy
11.3. Long-Term Therapy
12. Vulvodynia Treatment Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacies
12.3. Retail Pharmacies
12.4. Online Pharmacies
13. Vulvodynia Treatment Market, by Region
13.1. Asia-Pacific
13.2. Europe
13.3. North America
13.4. Latin America
13.5. Africa
13.6. Middle East
14. Vulvodynia Treatment Market, by Group
14.1. NATO
14.2. G7
14.3. BRICS
14.4. European Union
14.5. ASEAN
14.6. GCC
15. Vulvodynia Treatment Market, by Country
15.1. China
15.2. United States
15.3. Japan
15.4. India
15.5. Germany
15.6. United Kingdom
15.7. Australia
15.8. France
15.9. South Korea
15.10. Italy
15.11. Canada
15.12. Russia
15.13. Brazil
15.14. Mexico
15.15. Spain
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. FPNV Positioning Matrix, 2025
16.3. Market Concentration Analysis, 2025
16.3.1. Concentration Ratio (CR)
16.3.2. Herfindahl Hirschman Index (HHI)
16.4. Recent Developments & Impact Analysis, 2025
16.5. Product Portfolio Analysis, 2025
16.6. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Amgen Inc.
17.2. Bayer AG
17.3. BioMoi LLC
17.4. Cipla Limited
17.5. Desert Harvest
17.6. Good Clean Love
17.7. Initiator Pharma A/S
17.8. MAC Research Limited
17.9. Merck & Co., Inc.
17.10. NeuEve LLC
17.11. Novartis AG
17.12. Peptonic Medical AB
17.13. Sanofi S.A.
17.14. Solis Pelvic Health, LLC
17.15. Soul Source
17.16. SPM Therapeutics Inc.
17.17. Takeda Pharmaceutical Company Limited
17.18. Teva Pharmaceutical Industries Ltd.
17.19. VuVatech, LLC
17.20. YoniFlex
List of Figures
FIGURE 1. GLOBAL VULVODYNIA TREATMENT MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL VULVODYNIA TREATMENT MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL VULVODYNIA TREATMENT MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL VULVODYNIA TREATMENT MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 9. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY PRESCRIPTION STATUS, 2025 VS 2032 (%)
FIGURE 11. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY PRESCRIPTION STATUS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2032 (%)
FIGURE 13. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY DURATION, 2025 VS 2032 (%)
FIGURE 15. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY DURATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 17. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 21. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 23. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL VULVODYNIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 25. GLOBAL VULVODYNIA TREATMENT MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL VULVODYNIA TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL NON-PHARMACOLOGICAL TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL NON-PHARMACOLOGICAL TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL NON-PHARMACOLOGICAL TREATMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL PHYSICAL THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL PHYSICAL THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL PHYSICAL THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL PSYCHOLOGICAL THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL PSYCHOLOGICAL THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL PSYCHOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL NEUROMODULATION / DEVICE-BASED THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL NEUROMODULATION / DEVICE-BASED THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL NEUROMODULATION / DEVICE-BASED THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL PHARMACOLOGICAL TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL PHARMACOLOGICAL TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL PHARMACOLOGICAL TREATMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL TOPICAL TREATMENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL TOPICAL TREATMENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL TOPICAL TREATMENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL ORAL MEDICATIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL ORAL MEDICATIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL ORAL MEDICATIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL HORMONAL THERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL HORMONAL THERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL HORMONAL THERAPIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL PRESCRIPTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL PRESCRIPTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL PRESCRIPTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL OVER-THE-COUNTER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL OVER-THE-COUNTER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL OVER-THE-COUNTER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL FIRST-LINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL FIRST-LINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL FIRST-LINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL SECOND-LINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL SECOND-LINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL SECOND-LINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL THIRD-LINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL THIRD-LINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL THIRD-LINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL REFRACTORY CARE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL REFRACTORY CARE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL REFRACTORY CARE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY DURATION, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL SHORT-TERM THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL SHORT-TERM THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL SHORT-TERM THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL LONG-TERM THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL LONG-TERM THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL LONG-TERM THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 76. ASIA-PACIFIC VULVODYNIA TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 77. ASIA-PACIFIC VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 78. ASIA-PACIFIC VULVODYNIA TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 79. ASIA-PACIFIC VULVODYNIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 80. ASIA-PACIFIC VULVODYNIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 81. ASIA-PACIFIC VULVODYNIA TREATMENT MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 82. ASIA-PACIFIC VULVODYNIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 83. ASIA-PACIFIC VULVODYNIA TREATMENT MARKET SIZE, BY DURATION, 2017-2032 (USD MILLION)
TABLE 84. ASIA-PACIFIC VULVODYNIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 85. EUROPE VULVODYNIA TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 86. EUROPE VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 87. EUROPE VULVODYNIA TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 88. EUROPE VULVODYNIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 89. EUROPE VULVODYNIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 90. EUROPE VULVODYNIA TREATMENT MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 91. EUROPE VULVODYNIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 92. EUROPE VULVODYNIA TREATMENT MARKET SIZE, BY DURATION, 2017-2032 (USD MILLION)
TABLE 93. EUROPE VULVODYNIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 94. NORTH AMERICA VULVODYNIA TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 95. NORTH AMERICA VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 96. NORTH AMERICA VULVODYNIA TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 97. NORTH AMERICA VULVODYNIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 98. NORTH AMERICA VULVODYNIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 99. NORTH AMERICA VULVODYNIA TREATMENT MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 100. NORTH AMERICA VULVODYNIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 101. NORTH AMERICA VULVODYNIA TREATMENT MARKET SIZE, BY DURATION, 2017-2032 (USD MILLION)
TABLE 102. NORTH AMERICA VULVODYNIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 103. LATIN AMERICA VULVODYNIA TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 104. LATIN AMERICA VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 105. LATIN AMERICA VULVODYNIA TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 106. LATIN AMERICA VULVODYNIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 107. LATIN AMERICA VULVODYNIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 108. LATIN AMERICA VULVODYNIA TREATMENT MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 109. LATIN AMERICA VULVODYNIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 110. LATIN AMERICA VULVODYNIA TREATMENT MARKET SIZE, BY DURATION, 2017-2032 (USD MILLION)
TABLE 111. LATIN AMERICA VULVODYNIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 112. AFRICA VULVODYNIA TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 113. AFRICA VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 114. AFRICA VULVODYNIA TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 115. AFRICA VULVODYNIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 116. AFRICA VULVODYNIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 117. AFRICA VULVODYNIA TREATMENT MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 118. AFRICA VULVODYNIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 119. AFRICA VULVODYNIA TREATMENT MARKET SIZE, BY DURATION, 2017-2032 (USD MILLION)
TABLE 120. AFRICA VULVODYNIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 121. MIDDLE EAST VULVODYNIA TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 122. MIDDLE EAST VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 123. MIDDLE EAST VULVODYNIA TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 124. MIDDLE EAST VULVODYNIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 125. MIDDLE EAST VULVODYNIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 126. MIDDLE EAST VULVODYNIA TREATMENT MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 127. MIDDLE EAST VULVODYNIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 128. MIDDLE EAST VULVODYNIA TREATMENT MARKET SIZE, BY DURATION, 2017-2032 (USD MILLION)
TABLE 129. MIDDLE EAST VULVODYNIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 130. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 131. NATO VULVODYNIA TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 132. NATO VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 133. NATO VULVODYNIA TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 134. NATO VULVODYNIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 135. NATO VULVODYNIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 136. NATO VULVODYNIA TREATMENT MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 137. NATO VULVODYNIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 138. NATO VULVODYNIA TREATMENT MARKET SIZE, BY DURATION, 2017-2032 (USD MILLION)
TABLE 139. NATO VULVODYNIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 140. G7 VULVODYNIA TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 141. G7 VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 142. G7 VULVODYNIA TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 143. G7 VULVODYNIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 144. G7 VULVODYNIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 145. G7 VULVODYNIA TREATMENT MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 146. G7 VULVODYNIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 147. G7 VULVODYNIA TREATMENT MARKET SIZE, BY DURATION, 2017-2032 (USD MILLION)
TABLE 148. G7 VULVODYNIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 149. BRICS VULVODYNIA TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 150. BRICS VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 151. BRICS VULVODYNIA TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 152. BRICS VULVODYNIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 153. BRICS VULVODYNIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 154. BRICS VULVODYNIA TREATMENT MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 155. BRICS VULVODYNIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 156. BRICS VULVODYNIA TREATMENT MARKET SIZE, BY DURATION, 2017-2032 (USD MILLION)
TABLE 157. BRICS VULVODYNIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 158. EUROPEAN UNION VULVODYNIA TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 159. EUROPEAN UNION VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 160. EUROPEAN UNION VULVODYNIA TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 161. EUROPEAN UNION VULVODYNIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 162. EUROPEAN UNION VULVODYNIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 163. EUROPEAN UNION VULVODYNIA TREATMENT MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 164. EUROPEAN UNION VULVODYNIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 165. EUROPEAN UNION VULVODYNIA TREATMENT MARKET SIZE, BY DURATION, 2017-2032 (USD MILLION)
TABLE 166. EUROPEAN UNION VULVODYNIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 167. ASEAN VULVODYNIA TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 168. ASEAN VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 169. ASEAN VULVODYNIA TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 170. ASEAN VULVODYNIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 171. ASEAN VULVODYNIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 172. ASEAN VULVODYNIA TREATMENT MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 173. ASEAN VULVODYNIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 174. ASEAN VULVODYNIA TREATMENT MARKET SIZE, BY DURATION, 2017-2032 (USD MILLION)
TABLE 175. ASEAN VULVODYNIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 176. GCC VULVODYNIA TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 177. GCC VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 178. GCC VULVODYNIA TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 179. GCC VULVODYNIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 180. GCC VULVODYNIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 181. GCC VULVODYNIA TREATMENT MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 182. GCC VULVODYNIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 183. GCC VULVODYNIA TREATMENT MARKET SIZE, BY DURATION, 2017-2032 (USD MILLION)
TABLE 184. GCC VULVODYNIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 185. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 186. CHINA VULVODYNIA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 187. CHINA VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 188. CHINA VULVODYNIA TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 189. CHINA VULVODYNIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 190. CHINA VULVODYNIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 191. CHINA VULVODYNIA TREATMENT MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 192. CHINA VULVODYNIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 193. CHINA VULVODYNIA TREATMENT MARKET SIZE, BY DURATION, 2017-2032 (USD MILLION)
TABLE 194. CHINA VULVODYNIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 195. UNITED STATES VULVODYNIA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 196. UNITED STATES VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 197. UNITED STATES VULVODYNIA TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 198. UNITED STATES VULVODYNIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 199. UNITED STATES VULVODYNIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 200. UNITED STATES VULVODYNIA TREATMENT MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 201. UNITED STATES VULVODYNIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 202. UNITED STATES VULVODYNIA TREATMENT MARKET SIZE, BY DURATION, 2017-2032 (USD MILLION)
TABLE 203. UNITED STATES VULVODYNIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 204. JAPAN VULVODYNIA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 205. JAPAN VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 206. JAPAN VULVODYNIA TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 207. JAPAN VULVODYNIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 208. JAPAN VULVODYNIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 209. JAPAN VULVODYNIA TREATMENT MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 210. JAPAN VULVODYNIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 211. JAPAN VULVODYNIA TREATMENT MARKET SIZE, BY DURATION, 2017-2032 (USD MILLION)
TABLE 212. JAPAN VULVODYNIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 213. INDIA VULVODYNIA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 214. INDIA VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 215. INDIA VULVODYNIA TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 216. INDIA VULVODYNIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 217. INDIA VULVODYNIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 218. INDIA VULVODYNIA TREATMENT MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 219. INDIA VULVODYNIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 220. INDIA VULVODYNIA TREATMENT MARKET SIZE, BY DURATION, 2017-2032 (USD MILLION)
TABLE 221. INDIA VULVODYNIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 222. GERMANY VULVODYNIA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 223. GERMANY VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 224. GERMANY VULVODYNIA TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 225. GERMANY VULVODYNIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 226. GERMANY VULVODYNIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 227. GERMANY VULVODYNIA TREATMENT MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 228. GERMANY VULVODYNIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 229. GERMANY VULVODYNIA TREATMENT MARKET SIZE, BY DURATION, 2017-2032 (USD MILLION)
TABLE 230. GERMANY VULVODYNIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 231. UNITED KINGDOM VULVODYNIA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 232. UNITED KINGDOM VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 233. UNITED KINGDOM VULVODYNIA TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 234. UNITED KINGDOM VULVODYNIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 235. UNITED KINGDOM VULVODYNIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 236. UNITED KINGDOM VULVODYNIA TREATMENT MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 237. UNITED KINGDOM VULVODYNIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 238. UNITED KINGDOM VULVODYNIA TREATMENT MARKET SIZE, BY DURATION, 2017-2032 (USD MILLION)
TABLE 239. UNITED KINGDOM VULVODYNIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 240. AUSTRALIA VULVODYNIA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 241. AUSTRALIA VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 242. AUSTRALIA VULVODYNIA TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 243. AUSTRALIA VULVODYNIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 244. AUSTRALIA VULVODYNIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 245. AUSTRALIA VULVODYNIA TREATMENT MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 246. AUSTRALIA VULVODYNIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 247. AUSTRALIA VULVODYNIA TREATMENT MARKET SIZE, BY DURATION, 2017-2032 (USD MILLION)
TABLE 248. AUSTRALIA VULVODYNIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 249. FRANCE VULVODYNIA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 250. FRANCE VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 251. FRANCE VULVODYNIA TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 252. FRANCE VULVODYNIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 253. FRANCE VULVODYNIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 254. FRANCE VULVODYNIA TREATMENT MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 255. FRANCE VULVODYNIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 256. FRANCE VULVODYNIA TREATMENT MARKET SIZE, BY DURATION, 2017-2032 (USD MILLION)
TABLE 257. FRANCE VULVODYNIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 258. SOUTH KOREA VULVODYNIA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 259. SOUTH KOREA VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 260. SOUTH KOREA VULVODYNIA TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 261. SOUTH KOREA VULVODYNIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 262. SOUTH KOREA VULVODYNIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 263. SOUTH KOREA VULVODYNIA TREATMENT MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 264. SOUTH KOREA VULVODYNIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 265. SOUTH KOREA VULVODYNIA TREATMENT MARKET SIZE, BY DURATION, 2017-2032 (USD MILLION)
TABLE 266. SOUTH KOREA VULVODYNIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 267. ITALY VULVODYNIA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 268. ITALY VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 269. ITALY VULVODYNIA TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 270. ITALY VULVODYNIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 271. ITALY VULVODYNIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 272. ITALY VULVODYNIA TREATMENT MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 273. ITALY VULVODYNIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 274. ITALY VULVODYNIA TREATMENT MARKET SIZE, BY DURATION, 2017-2032 (USD MILLION)
TABLE 275. ITALY VULVODYNIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 276. CANADA VULVODYNIA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 277. CANADA VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 278. CANADA VULVODYNIA TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 279. CANADA VULVODYNIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 280. CANADA VULVODYNIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 281. CANADA VULVODYNIA TREATMENT MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 282. CANADA VULVODYNIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 283. CANADA VULVODYNIA TREATMENT MARKET SIZE, BY DURATION, 2017-2032 (USD MILLION)
TABLE 284. CANADA VULVODYNIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 285. RUSSIA VULVODYNIA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 286. RUSSIA VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 287. RUSSIA VULVODYNIA TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 288. RUSSIA VULVODYNIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 289. RUSSIA VULVODYNIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 290. RUSSIA VULVODYNIA TREATMENT MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 291. RUSSIA VULVODYNIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 292. RUSSIA VULVODYNIA TREATMENT MARKET SIZE, BY DURATION, 2017-2032 (USD MILLION)
TABLE 293. RUSSIA VULVODYNIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 294. BRAZIL VULVODYNIA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 295. BRAZIL VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 296. BRAZIL VULVODYNIA TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 297. BRAZIL VULVODYNIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 298. BRAZIL VULVODYNIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 299. BRAZIL VULVODYNIA TREATMENT MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 300. BRAZIL VULVODYNIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 301. BRAZIL VULVODYNIA TREATMENT MARKET SIZE, BY DURATION, 2017-2032 (USD MILLION)
TABLE 302. BRAZIL VULVODYNIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 303. MEXICO VULVODYNIA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 304. MEXICO VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 305. MEXICO VULVODYNIA TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 306. MEXICO VULVODYNIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 307. MEXICO VULVODYNIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 308. MEXICO VULVODYNIA TREATMENT MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 309. MEXICO VULVODYNIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 310. MEXICO VULVODYNIA TREATMENT MARKET SIZE, BY DURATION, 2017-2032 (USD MILLION)
TABLE 311. MEXICO VULVODYNIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 312. SPAIN VULVODYNIA TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 313. SPAIN VULVODYNIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 314. SPAIN VULVODYNIA TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 315. SPAIN VULVODYNIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 316. SPAIN VULVODYNIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 317. SPAIN VULVODYNIA TREATMENT MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 318. SPAIN VULVODYNIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2017-2032 (USD MILLION)
TABLE 319. SPAIN VULVODYNIA TREATMENT MARKET SIZE, BY DURATION, 2017-2032 (USD MILLION)
TABLE 320. SPAIN VULVODYNIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 321. GLOBAL VULVODYNIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
TABLE 322. GLOBAL VULVODYNIA TREATMENT MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

Companies Mentioned

  • Amgen Inc.
  • Bayer AG
  • BioMoi LLC
  • Cipla Limited
  • Desert Harvest
  • Good Clean Love
  • Initiator Pharma A/S
  • MAC Research Limited
  • Merck & Co., Inc.
  • NeuEve LLC
  • Novartis AG
  • Peptonic Medical AB
  • Sanofi S.A.
  • Solis Pelvic Health, LLC
  • Soul Source
  • SPM Therapeutics Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • VuVatech, LLC
  • YoniFlex

Table Information

Report AttributeDetails
No. of Pages196
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 2.25 Billion
Forecasted Market Value ( USD ) by 2032 $ 3.28 Billion
Compound Annual Growth Rate6.3%
Regions CoveredGlobal
No. of Companies Mentioned20

Related Topics

Related Reports

Vulvodynia Treatment Market Report 2026 - Product Image

Vulvodynia Treatment Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Diagnostic Gynecologic and Obstetric Pathology. Edition No. 3 - Product Image

Diagnostic Gynecologic and Obstetric Pathology. Edition No. 3

  • Book
Atlas of Pelvic Anatomy and Gynecologic Surgery. Edition No. 5 - Product Image

Atlas of Pelvic Anatomy and Gynecologic Surgery. Edition No. 5

  • Book
Women and Health. Edition No. 3 - Product Image

Women and Health. Edition No. 3

  • Book
Dysmenorrhea Treatment Market - Global Forecast 2026-2032 - Product Image

Dysmenorrhea Treatment Market - Global Forecast 2026-2032

  • Report
  • 195 Pages
  • Global
From

About the Vulvodynia Drug Market

Vulvodynia is a chronic pain disorder that affects the vulva, the external female genitalia. It is estimated to affect up to 16% of women in the United States. The Vulvodynia Drug market is a subset of the Sexual and Reproductive Health Drugs market, which includes medications used to treat conditions related to sexual health, such as contraception, infertility, and sexually transmitted infections. Vulvodynia drugs are used to treat the pain associated with the condition, as well as to reduce inflammation and improve overall vulvar health. Common treatments include topical creams, oral medications, and physical therapy. In some cases, surgery may be recommended. The Vulvodynia Drug market is a growing field, with many companies developing new treatments and therapies. Some of the companies in the market include Allergan, Pfizer, Merck, and Bayer. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.